Details of the Drug

General Information of Drug (ID: DM8YU2F)

Drug Name
Mepenzolate
Synonyms
Cantil; Cantilaque; Cantilon; Cantril; Colibantil; Colopiril; Colum; Delevil; Eftoron; Gastropidil; Glycophenylate; Mepenzolon; Tralanta; Trancolon; Trokonil; Bromure de mepenzolate; Bromuro de mepenzolato; MEPENZOLATE BROMIDE; Mepenzolate Methylbromide; Mepenzolati bromidum; Mepenzolic acid; Mepenzolone Bromide; JB 340; Bromure de mepenzolate [INN-French]; Bromuro de mepenzolato [INN-Spanish]; Cantil (TN); Mepenzolati bromidum [INN-Latin]; Mepenzolic acid, bromine salt; Mepenzolate bromide (JP15/INN); Mepenzolate bromide [INN:BAN:JAN]; N-Methyl-3-piperidyl benzilate methobromide; N-Methyl-3-piperidyl benzilate methyl bromide; N-Methyl-3-piperidyldiphenylglycolate methobromide; N-methyl-3-piperidylbenzilate methyl bromide; Benzilic acid, 1-methyl-3-piperidyl ester methobromide; Benzilic acid, ester with 3-hydroxy-1,1-dimethylpiperidinium bromide; Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-, bromide; Piperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester); Piperidinium, 3-hydroxy-1,1-dimethyl-, bromide, benzilate; Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-(VAN); Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-, bromide; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate bromide; 1-Methyl-3-piperidyl benzilate methyl bromide; 1-Methyl-3-piperidyl benzilate methylbromide; 2-(1,1-dimethylpiperidin-1-ium-3-yl)oxy-2-oxo-1,1-diphenylethanolate; 2-[(1,1-dimethylpiperidinium-3-yl)oxy]-2-oxo-1,1-diphenylethanolate; 3-((Hydroxydiphenylacetyl)oxy)-1,1-dimethylpiperidinium bromide; 3-Hydroxy-1,1-dimethylpiperidinium bromide benzilate; 3-{[hydroxy(diphenyl)acetyl]oxy}-1,1-dimethylpiperidinium bromide
Indication
Disease Entry ICD 11 Status REF
Gastrointestinal disease DE2Z Approved [1], [2]
Peptic ulcer DA61 Approved [1], [2]
Therapeutic Class
Parasympatholytics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 340.4
Topological Polar Surface Area (xlogp) 3.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C21H26NO3+
IUPAC Name
(1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate
Canonical SMILES
C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C
InChI
InChI=1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1
InChIKey
GKNPSSNBBWDAGH-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4057
ChEBI ID
CHEBI:94411
CAS Number
25990-43-6
DrugBank ID
DB04843
TTD ID
D0FV3V
VARIDT ID
DR00973
ACDINA ID
D00396

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Antagonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mepenzolate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Mepenzolate and Oliceridine. Acute pain [MG31] [14]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Mepenzolate and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [15]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Mepenzolate and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [15]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Mepenzolate and Cariprazine. Bipolar disorder [6A60] [16]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Mepenzolate and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [17]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Mepenzolate and Revefenacin. Chronic obstructive pulmonary disease [CA22] [17]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Mepenzolate and OPC-34712. Depression [6A70-6A7Z] [16]
Nebivolol DM7F1PA Moderate Additive CNS depression effects by the combination of Mepenzolate and Nebivolol. Hypertension [BA00-BA04] [18]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Mepenzolate and Belladonna. Infectious gastroenteritis/colitis [1A40] [16]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Mepenzolate and ITI-007. Insomnia [7A00-7A0Z] [16]
R0-93877 DMM4U9G Moderate Antagonize the effect of Mepenzolate when combined with R0-93877. Irritable bowel syndrome [DD91] [19]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Mepenzolate and Methylscopolamine. Peptic ulcer [DA61] [16]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Mepenzolate and Iloperidone. Schizophrenia [6A20] [16]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Mepenzolate and Asenapine. Schizophrenia [6A20] [16]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Mepenzolate and Acrivastine. Vasomotor/allergic rhinitis [CA08] [15]
⏷ Show the Full List of 15 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrazine yellow E00409 164825 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Mepenzolate 25 mg tablet 25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010679.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Isolation of cholinergic active ingredients in aqueous extracts of Mareya micrantha using the longitudinal muscle of isolated guinea-pig ileum as a pharmacological activity marker. J Ethnopharmacol. 1995 Mar;45(3):215-22.
4 Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
5 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
6 Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
7 Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
8 Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
9 Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
11 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
12 Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
13 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
14 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
15 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
16 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
17 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".